Leukemia

CD19
؉ and CD20 ؉ B cells from the peripheral blood of patients with multiple myeloma are not infected with human herpesvirus 8 TO 
THE EDITOR
Conflicting results concerning the presence of the human herpesvirus 8 (HHV-8) in dendritic cells of patients with multiple myeloma (MM) have led to a controversial discussion about its role in the pathogenesis of this malignancy.
1,2 To further investigate the association of HHV-8 with MM we searched for viral sequences in the peripheral CD19 + and CD20 + B cell fractions of myeloma patients, referring to the B cell tropism of this virus observed in Kaposi's sarcoma, multicentric Castleman's disease and primary effusion lymphoma and to the successful transfer of HHV-8 to cultured CD19 + B cells from healthy donors.
3-6
Peripheral blood (PB) samples of 16 patients were included into the study. The patient characteristics are summarized in Table 1 . CD19
+
and CD20
+ B cells were enriched using the MiniMACS system (Miltenyi Biotec, Bergisch Gladbach, Germany). After Ficoll-Hypaque density centrifugation (Biochrom, Berlin, Germany) mononuclear cells (MNCs) were washed twice in PBS containing 0.5% bovine serum albumin (BSA). CD19
+ cells were then labeled with anti-CD19 Microbeads (Miltenyi Biotec). For the purification of CD20 + cells, pooled polyclonal human IgG (Endobulin; Baxter, Mü nchen, Germany) was added to a final concentration of 5%. Staining was done with a biotinylated anti-CD20 antibody, the IDEC-C2B8 (kindly provided by Dr Riedel, Roche, Grenzach-Wyhlen, Germany) for 20 min at 4°C. After incubation with the IDEC-C2B8, the cells were washed with PBS containing 0.5% BSA and 5% Endobulin and incubated with streptavidin-coupled MicroBeads (Miltenyi Biotec) for 20 min at 4°C. CD19/CD20 bearing cells were enriched over two consecutive MS+ selection columns. The frequency of CD19 + and CD20 + cells was assessed by immunofluorescence analysis using a FACScan (Beckton Dickinson, Heidelberg, Germany). Genomic DNA was isolated by DNAzol (Gibco BRL, Eggenstein, Germany) according to the manufacturer's instructions. To ensure the integrity of the isolated DNA, a sequence from the bcl-2 proto-oncogene was amplified. PCR analyses focused on the open reading frame (ORF) 26 of the HHV-8 genome using a nested primer assay. 7 Amplification was performed twice with 2 g of DNA (equivalent to 330 000 cells), except for the CD19 + fractions of patients 6 and 15, as well as for the CD20 + fraction of patient No. 9. In these cases only 1.5 and 1 g DNA respectively, could be reproducibly assessed. PCR assays were performed as previously described. 8 Primers were the following: 5Ј-CTC GCT CGC CCA GGT ACA TGG ACA GAT CGT CAA G-3Ј and 5Ј-CTG GTT CGG CCC ACG GAC TAC ATC CAA ATT ATG CAG-3Ј. Three l of first round synthesis were re-amplified with 5Ј-CTC GCT CGC CCA GAT CCG TGT TGT CTA CGT CCA G-3Ј and 5Ј-CTG GTT CGG CCC ATT TTA GCC GAA AGG ATT CCA CC-3Ј as second round primers All primers were elongated at their 5Ј-end with so-called cloning tails (indicated in italics) to facilitate cloning of the obtained PCR products. After electrophoresis of the whole PCR assay, Southern blotting and hybridization were done as previously described. 8 The sensitivity of the PCR assay was tested using a plasmid comprising the first round PCR product obtained from a DNA sample of a Kaposi's sarcoma lesion. For cloning the DNA was electrophoresed, the expected band excised from the gel and purified using the EasyPure DNA purification Kit (Biozym, Gö ttingen, Germany). Plasmids carrying the ORF 26 sequence were isolated from bacterial clones and purified using the QIAwell 8 Plus system (Qiagen, Hilden, Germany). The concentration of plasmid DNA was determined by optical density measurement. Plasmids were diluted in 10-fold steps The proportion of CD19 + cells in PB varied between 2.7 and 39.5% (median, 13.5%) and corresponded to that of the CD20 + cells (median, 13.1%; range, 3.6-26.7%). After double MACS sorting the purities of the CD19 + enriched fractions ranged from 80.2 to 99.2% (median, 95.1%), and from 81.8 to 99.5% (median, 98.0%) for the CD20 + cell fractions.
Analysis of the 16 CD19
+ and of the 11 CD20 + enriched and depleted cell fractions revealed no HHV-8-specific amplification products, although the positive control comprising four copies of plasmid DNA carrying the ORF 26 specific sequence was clearly visible. Second round amplification verified this PCR-negativity after gel electrophoresis and subsequent hybridization (Figure 1) . In order to confirm the PCR sensitivity the expected frequencies of positive reactions were calculated to be 100% (for an average of 100 copies of target DNA per reaction tube), 100% (for 33 copies), 99.5% (for 10 copies), 95% (for three copies), 63% (for one copy) and 26% (for 0.3 copies). For all copy numbers tested the pattern of PCR results obtained did not differ by more than one from the calculated number of positive PCR results, thus demonstrating single hit capability of the primer pairs used in the nested PCR assay.
In our study, no HHV-8 sequences were detected, neither in the enriched B cell fractions nor in the corresponding depleted fractions, although newly diagnosed patients, as well as those with progressive disease, were included. Suggesting the absence of the virus in the peripheral blood of MM patients, these data are in line with those groups who failed to detect HHV-8 in the peripheral blood and correspond to our previous findings that leukapheresis products as well as bone marrow-derived dendritic cells do not harbor HHV-8 specific DNA. 8, 9 Thus, we do not favor a pathogenic role of HHV-8 in MM. 
